Trump Action Archive

Supporting reports

• Supreme Court Allows Revocation of Temporary Protected Status for Migrants — On May 30, 2025, the U.S.
• Motion granted — Svitlana Doe v. Noem (D. Mass.) 1:25-cv-10495 — The Supreme Court allowed the administration to temporarily end the humanitarian parole program that granted provisional legal status to over 530,000 migrants from Cuba, Haiti, Nicaragua, and Venezuela (CHNV), enabling
• Supreme Court Grants Stay in Noem v. Doe — On May 30, 2025, the Supreme Court granted the federal government's request for a stay in the case of Noem v.

Supporting reports

• Environmental Impact Statements Notice by EPA — The Environmental Protection Agency (EPA) has published a notice of availability for several Environmental Impact Statements (EISs) filed between May 19 and May 23, 2025.
• EPA Announces Pesticide Program Dialogue Committee Meeting — The Environmental Protection Agency (EPA) announced a virtual meeting of the Pesticide Program Dialogue Committee (PPDC) scheduled for June 17, 2025.

Supporting reports

• EPA Receives Requests to Voluntarily Cancel Certain Pesticide Registrations — The Environmental Protection Agency (EPA) announced the receipt of requests from registrants to voluntarily cancel certain pesticide registrations.

Supporting reports

• FDA Determines ACTIGALL Was Not Withdrawn for Safety or Effectiveness — The Food and Drug Administration (FDA) determined that ACTIGALL (ursodiol) capsules, 150 mg, were not withdrawn from sale for reasons of safety or effectiveness.
• FDA Determines COREG CR Was Not Withdrawn for Safety or Effectiveness — The FDA announced that COREG CR (carvedilol phosphate) extended-release capsules, in various dosages, were not withdrawn from sale due to safety or effectiveness concerns.

Supporting reports

• FDA Determines Regulatory Review Period for LOQTORZI — The Food and Drug Administration (FDA) has determined the regulatory review period for the human biologic product LOQTORZI, which is used for treating nasopharyngeal carcinoma.

Supporting reports

• FDA Issues Draft Guidance on Replacing Color Additives in Drug Products — The Food and Drug Administration (FDA) has released a draft guidance for industry on replacing color additives in approved or marketed drug products.

Supporting reports

• FDA Releases Annual Report on Postmarketing Requirements — The Food and Drug Administration (FDA) has published its annual report on the performance of drug and biologics firms in conducting postmarketing requirements and commitments for fiscal year 2023.

Supporting reports

• FDA Withdraws Approval of Two New Drug Applications — The Food and Drug Administration (FDA) has withdrawn approval for two new drug applications (NDAs) from Meda AB and B.

Supporting reports

• Supreme Court Allows Revocation of Temporary Protected Status for Migrants — On May 30, 2025, the U.S.
• Motion granted — Svitlana Doe v. Noem (D. Mass.) 1:25-cv-10495 — The Supreme Court allowed the administration to temporarily end the humanitarian parole program that granted provisional legal status to over 530,000 migrants from Cuba, Haiti, Nicaragua, and Venezuela (CHNV), enabling
• Supreme Court Grants Stay in Noem v. Doe — On May 30, 2025, the Supreme Court granted the federal government's request for a stay in the case of Noem v.

Supporting reports

• US court halts deportation flight to South Sudan — In late May, a US district judge in Boston intervened to stop a deportation flight to South Sudan, ruling that the Trump administration had violated an earlier order.

Supporting reports

• Appeal filed — Mennonite Church USA et al. v. United States Department of Homeland Security et al (D.D.C.) 1:25-cv-00403 — Plaintiffs appealed Judge Friedrich's order denying their preliminary injunction motion to the D.C.

Supporting reports

• Case update — J. Doe 4 v. Musk (D. Md.) 8:25-cv-00462 — Plaintiffs filed their second amended class action complaint , but did not amend any of the allegations included in the April 17 amended complaint.

Supporting reports

• Motion denied — American Federation Of Government Employees, AFL-CIO v. Trump (N.D. Cal.) 3:25-cv-03698 — The Ninth Circuit denied the Defendants' motion for a stay.

Supporting reports

• Motion granted — National TPS Alliance et al. v. Noem (N.D. Cal.) 3:25-cv-01766 — The district court granted Plaintiffs' motion to prevent Defendants from invalidating work permits and other documents to a subset of the Venezuelan Plaintiffs.

Supporting reports

• Preliminary injunction ruling — American Public Health Association v. National Institutes of Health (D. Mass.) 1:25-cv-10787 — Judge William Young collapsed the motion for a preliminary injunction into a motion to dismiss and granted the Defendants' motion to dismiss three counts but denied the motion to dismiss on all other counts.

Supporting reports

• Temporary restraining order ruling — RFE/RL, Inc. v. Lake (D.D.C.) 1:25-cv-00799 — The district court granted a temporary restraining order requiring the government to immediately disburse $12,174,979 to cover RFE/RL's expenditures for the month of May 2025.
• Federal Judge Orders Release of Funds to Radio Free Europe/Radio Liberty — A federal judge ordered the Trump administration to release over $12 million in previously allocated funding to Radio Free Europe/Radio Liberty.

Supporting reports

• Temporary restraining order ruling — Valuta Corporation, Inc. v. Financial Crimes Enforcement Network (W.D. Tex.) 3:25-cv-00191 — Plaintiffs filed a motion for a temporary restraining order .

Supporting reports

• Supreme Court denies stay in Kapoor v. DeMarco — The Supreme Court, through Associate Justice Sonia Sotomayor, vacated a previously issued stay and denied the application for a stay in the case of Monika Kapoor v.

Supporting reports

• Federal Election Commission Sunshine Act Meeting Notice — The Federal Election Commission announced a closed meeting scheduled for June 3, 2025, at 11:00 a.m.

Supporting reports

• FBI investigates impersonation of White House chief of staff Susie Wiles — The FBI is investigating an impersonation incident involving Susie Wiles, the White House chief of staff.

Supporting reports

• State Department Plans to Create 'Office of Remigration' — The U.S.

Supporting reports

• Carlton Reico Mallard Jr. Debarred by FDA — The Food and Drug Administration (FDA) has issued a final debarment order against Carlton Reico Mallard Jr., prohibiting him from importing or offering for import any drug into the United States for 10 years.
• Quality Poultry and Seafood, Incorporated Debarred by FDA — The Food and Drug Administration (FDA) has issued a final debarment order against Quality Poultry and Seafood, Incorporated (QPS), prohibiting the company from importing food into the United States for five years.
• FDA Classifies Anti-Mullerian Hormone Test System — The Food and Drug Administration (FDA) has classified the anti-mullerian hormone test system into class II (special controls) to ensure safety and effectiveness.

Supporting reports

• EPA Establishes Pesticide Tolerances for Florylpicoxamid — The Environmental Protection Agency (EPA) has established tolerances for residues of the fungicide florylpicoxamid in various agricultural commodities, including barley, wheat, and canola.

Supporting reports

• FDA Announces Second Annual Animal Drug User Fee Educational Conference — The Food and Drug Administration (FDA) announced the Second Annual Animal Drug User Fee Educational Conference, scheduled for July 15, 2025.

Supporting reports

• FDA Classifies Inherited Nucleotide Repeat Disorder DNA Test — The Food and Drug Administration (FDA) has classified the inherited nucleotide repeat disorder DNA test into class II (special controls) to ensure safety and effectiveness.
• FDA Classifies Plazomicin Test System as Class II Device — The Food and Drug Administration (FDA) has classified the plazomicin test system as a class II device with special controls.
• FDA Classifies Urethral Opening System for BPH as Class II — The Food and Drug Administration (FDA) has classified the temporarily-placed urethral opening system for symptoms of benign prostatic hyperplasia (BPH) into class II with special controls.